Company intelligence / Profile preview

MTI-II Partners

Oxford, Oxfordshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

MTI Partners is a prominent United Kingdom-based venture capital firm that specializes in early-stage technology investments, with a significant historical focus on the life sciences, medical technology, and digital health sectors. The firm manages several funds, including the MTI-II (MTI 2) partnership, which has provided critical seed and Series A funding to numerous innovative startups in diagnostics, drug delivery, and specialized therapeutics. MTI Partners is known for taking an active role in its portfolio companies, providing both strategic guidance and capital to help transition academic research into commercially viable healthcare products. Their portfolio has included notable companies such as Oxford Immunotec and PolyTherics (now part of Abzena).

Industry: Investors

Beyond the preview

Go deeper on MTI-II Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTI-II Partners.

Explore the full profile